Status:
NOT_YET_RECRUITING
The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Conditions:
Relapsed B-ALL
CAR T-cells
Eligibility:
All Genders
Brief Summary
Acute lymphoblastic leukemia (ALL) is a malignant proliferation of immature lymphoid cells within the bone marrow, blood, and extramedullary sites. According to the SEER Cancer Statistics Review, the ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients (adults and pediatrics) with confirmed diagnosis with B-ALL and receipt CD19-targeted CAR-T cell therapy and have diagnostic or post -treatment BM or PB samples processed with a standard B-ALL immunophenotyping panel. with the presence of CD45, CD19, CD34, and CD38 in the antibody panel.
Exclusion
Key Trial Info
Start Date :
May 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06993766
Start Date
May 20 2025
End Date
May 31 2030
Last Update
May 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.